Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

Darrell Hoi-San TanMaria Jose RolonMaria Ines FigueroaOmar SuedAna GunRupert KaulJanet M RaboudLeah SzadkowskiMark W HullSharon L WalmsleyPedro Cahnnull null

Published in: PloS one (2019)

In addition to having virologic non-inferiority, LPV/r+3TC dual therapy is generally associated with similar inflammatory biomarker levels over 48 weeks compared to LPV/r+2NRTIs triple therapy in treatment-naïve adults. Further study of dual treatment regimens is warranted.

Keyphrases

oxidative stress
cell therapy